Background: In recognition of potential for increased overdose risk, drug labels for
analogues), the National Center for Health Statistics reported that nearly half of all opioid overdoses in 2016 were caused by prescription opioids, and that over 15 000 individuals fatally overdosed on prescription opioids in 2015 alone. 4 Serious public health concerns about opioid-related harms need to be addressed in the context of their value in pain management. Opioid analgesics play an important role in healthcare, providing relief for patients experiencing moderate to severe pain. It is estimated that between 11% and 31% adults in the United States suffer from chronic pain, and pain management therapy in these patients is complex. [5] [6] [7] The US Centers for Disease Control and Prevention (CDC) published guidelines in 2016 for prescribing opioids for chronic pain, stating that clinicians should prescribe the lowest effective dosage when initiating opioid therapy and "should avoid increasing dosage to 90 MME or more per day." 8 The United States Food and Drug Administration (FDA) approved product labels state that certain dosages of extended-release and long-acting (ER/LA) opioids should only be prescribed to patients with prior established opioid tolerance (at least 60 morphine milligram equivalents [MME] for 1 week or longer). 9, 10 Establishing opioid tolerance before initiation of higher dose ER/LA opioids is a component of the FDA risk evaluation and mitigation strategies for these drugs. However, studies have reported that between 40% and 74% of patients do not meet label recommendations for opioid tolerance, [11] [12] [13] and that older adults are at higher risk of receiving inappropriately high dosages. 9, 10, 13 Past studies have also found that high opioid dosages and ER/LA formulations are associated with increased risk of overdose; however, little has been published on opioid titration, dosing strategies, and the risk of adverse outcomes. [14] [15] [16] [17] [18] [19] The primary objective of this study was to describe a population of commercially insured adults in the United States initiating a daily dose ≥90 MME ER/LA opioids and to evaluate the proportion of initiators without prior opioid tolerance. The secondary objective was to examine whether opioid tolerance was associated with risk of clinically recognized opioid poisoning. 
| Eligible population
We identified patients initiating a daily dose of ER/LA opioids greater than or equal to 90 MME per day and refer to this as the index date.
Focus on this population reflects the Centers for Disease Control and Prevention Guidelines for Prescribing Opioids for Chronic Pain, which state that clinicians should avoid prescribing dosages of 90 MME or more per day, and any decisions to do so should be carefully justified. 8 Eligible patients initiated 1 of 9 ER/LA opioid analgesics covered under the ER/LA Opioid Analgesic risk evaluation and mitigation strategies:
buprenorphine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, and tapentadol. The methadone products included in this study were limited to solid oral formulations.
Liquid formulations are used primarily for medication-assisted treatment of opioid addiction and were excluded. Buprenorphine was limited to the transdermal patch and did not include oral formulations indicated and used primarily for addiction treatment.
We included adults aged 18 years or older with at least 365 days of continuous insurance enrollment prior to their index date. We applied a 365-day washout period during which adults had no prescription claims for an ER/LA opioid with a dose ≥90 MME to define incident high-dose use and collected baseline health information in the same period ( Figure 1 ). Patients were excluded if they had any procedure or diagnoses codes indicating naloxone administration, opioid poisoning, opioid addiction, or opioid abuse during baseline, or utilization of hospice services as these patients are likely to be receiving end-of-life care ( Figure S1 ).
We additionally identified patients initiating lower dosages of ER/ LA opioids to compare risk of clinically recognized opioid poisoning among those receiving ≥90 MMEs, regardless of tolerance, to those receiving lower dosages.
| Opioid tolerance definition
Using all claims for opioid prescriptions (immediate release and ER/LA) dispensed in the 90 days prior to index date, daily opioid exposure was computed from the date of prescription fill, quantity dispensed, and days'
KEY POINTS
• We found that 38% of adults starting extended-release and long-acting opioids of 90 morphine milligram equivalents or greater did not have evidence of opioid tolerance in the prior 2 weeks.
• Fentanyl was the most commonly prescribed high-dose extended-release and long-acting (35% of initiators), followed by oxycodone (30% of initiators).
• Methadone initiators had the highest proportion of patients (44%) without evidence of prior opioid tolerance, followed by fentanyl (42%).
• Patients without prior opioid tolerance were at 37% increased risk of clinically recognized opioid poisoning in the following 7 days (adjusted hazard ratios = 1.37, 95% confidence interval, 1.07-1.76).
• Patients initiating dosages of 90 morphine milligram equivalents or greater regardless of prior tolerance were at 81% increased risk of opioid poisoning in the following 7 days compared with those initiating dosages between 20 and 50 MME.
40supply values assuming perfect adherence. Dosage strengths were ascertained from National Drug Code identifiers and were converted to MME. 20 Dosage per day (daily MME) was calculated as follows:
Daily MME ¼ MME Conversion * dosage * quantity dispensed days ′ supplied :
Exposure began on the day of prescription fill date, lasting until the days supplied expired. Prescriptions with overlapping days of coverage were summed to calculate total opioid exposure per day.
Patients exposed to at least 60 MME daily for at least 7 out of 14 days prior to the index date were defined as opioid tolerant. 9, 10 Claimsbased identification of opioid tolerance was based on FDA drug labels, and we used an algorithm similar to those used in prior publications on opioid tolerance. [11] [12] [13] We conducted multiple sensitivity analyses (described below) to consider the robustness of our findings under different assumptions.
| Outcomes
Opioid poisoning was defined using International Classification of Diseases, Ninth Revision, Clinical Modification ICD-9-CM diagnosis codes billed in inpatient, outpatient, or emergency room settings (Table   S1 ). 21, 22 Because of the acute nature of opioid poisoning, the time immediately following high-dose initiation was of greatest interest.
We initially focused on outcomes within 30 days after index date, while an extended follow-up examined events occurring 31 to 90 and 91 to 365 days following the index date. Evaluation of cumulative incidence functions suggested significant heterogeneity of hazard ratio (HR) violating proportional hazards assumption in the first 30 days; thus, we added an additional window analyzing clinically recognized opioid poisoning within 7 days following initiation. This short-term outcome is consistent with the acute nature of opioid poisoning outcomes.
In-hospital death that was not identified as opioid poisoning and hospice care during follow-up were analyzed as competing risks. 
| Statistical analyses
We first describe the proportion of patients initiating ≥90 MME per day who have evidence of prior established opioid tolerance overall and by drug. Sensitivity analyses described below vary the definition of claims-based opioid tolerance.
Our secondary aim assessed the association between opioid tolerance prior to initiating ≥90 MME and the risk of clinically recognized opioid poisoning. To adjust for measured confounding, we fit a multivariable logistic regression model to estimate the probability of being categorized as tolerant versus nontolerant as a function of demographic variables (age, sex, region, and year of initiation), pain diagnoses, comorbidities, other medication use, and history of inpatient and emergency room visits during the 365-day baseline period (Table 1 includes all relevant covariates). Using each individual's predicted probability of being tolerant, we applied stabilized inverse probability of treatment weights (IPTW) to standardize the distribution of baseline covariates of both those with and without claims-based evidence of opioid tolerance to the distribution of the total study population, thereby removing measured confounding. Propensity scores were reestimated in each drug-specific analysis ( Figure S2 ).
We used the Fine and Gray method to model cumulative incidence curves accounting for competing risks of hospice care and inhospital death. 23 We used Cox proportional hazards models allowing for interactions with follow-up time to estimate distinct associations for 0-7, 8-30, 31-90, and 91-365 days following initiation. We present unadjusted and IPTW adjusted HRs for adverse outcomes comparing those with and without opioid tolerance overall, within subpopulations based on specific active ingredients, and for varying time periods during follow-up. We additionally report HRs for opioid poisoning among those receiving ≥90 MME, regardless of tolerance, compared with those receiving lower dosages. Ninety-five percent confidence intervals (CI) were estimated using the Wald statistic with a robust sandwich estimator.
All analyses were conducted in SAS 9.4 (Cary, NC). This study was reviewed by the University of North Carolina at Chapel Hill institutional review board (Study 16-1545) and determined to be exempt.
| Sensitivity analyses
We conducted 5 sensitivity analyses. To evaluate whether results were sensitive to the time-based definition of opioid tolerance used in our primary analysis, our first sensitivity analysis mirrored prior publications, shortening the tolerance window to the 7 days immediately prior to high-dose initiation. 11, 13 A second sensitivity analysis extended the tolerance window from 7 out of the previous 14 days to 7 out of the previous 30 days. Because we did not have information about drugs administered during inpatient hospitalizations, a third sensitivity analysis excluded patients with any inpatient stays during the 14-day tolerance window. 24 Our fourth sensitivity analysis assumed patients received at least 60 MME for all days during a hospital stay, representing the most extreme case of misclassified opioid exposures during hospitalizations. Lastly, our fifth sensitivity analysis focused on patients initiating ER/LA opioids of 100 MME or greater, as this cutoff is commonly used in drug labeling and other opioid research. 25 We conducted 1 post-hoc sensitivity analysis excluding patients whose index prescription was for a methadone product, because drug specific analyses indicated the methadone patients may have different risk profiles compared with patients initiating other opioids.
| Bias analysis
We used validated ICD-9-CM codes to identify opioid poisoning events, with prior studies finding that these codes have a specificity of 99.9% and sensitivity of 25%, and are helpful tools to enable population-level research monitoring overdose rates. 26, 27 In studies estimating relative effects, high outcome specificity is valued over outcome sensitivity, as perfect specificity results in unbiased relative effect estimates even when sensitivity is low, assuming nondifferential sensitivity between exposure groups. 28 We know of no studies that have examined whether the sensitivity of these codes varies by opioid tolerance status. In the absence of these data, we conducted a simple bias analysis, varying the sensitivity of ICD-9-CM codes in defining opioid poisoning, examining the impact of potential differences in sensitivity between nontolerant and tolerant patients. A lower sensitivity among nontolerant patients compared with tolerant patients would imply that a larger proportion of undetected fatal overdoses occur in nontolerant patients. Meanwhile, a higher sensitivity among nontolerant patients would imply that a larger proportion of fatal overdoses are captured in nontolerant patients.
| RESULTS
We identified 372 038 individuals initiating ER/LA opioids of ≥90 MME between January 1, 2007, and September 30, 2015. The mean age of all initiators was 54.8 years, and 46% were male. The most common chronic pain diagnoses in the 90 days prior to initiation were back pain (55%), arthritis (38%), and joint pain (21%). Over 12% of patients had no pain-related diagnosis codes in the 90-days prior to initiation.
Nearly half (46%) of all initiators received anxiolytics during baseline, and 43% of patients filled prescriptions for benzodiazepines during the 90-day baseline period (Table 1) . Fentanyl was the most common ≥90 MME ER/LA opioid prescribed (35%), followed by oxycodone (30%), morphine (17%), and methadone (11%). Overall, these 4 drugs accounted for 93% of ER/LA opioids among all initiators, and drug-specific results were limited to these 4 opioid substances (Table 2 ).
| Opioid tolerance
Among 372 038 patients initiating ER/LA dosages of 90 MME or greater, 38% did not have established opioid tolerance prior to initiation based on our claims-derived algorithm. Methadone initiators had the highest proportion of patients (44%) without evidence of prior opioid tolerance, followed by fentanyl (42%) ( Table 2 ).
Patients without prior established opioid tolerance were more likely to be in either the youngest age category (18-24 years of age)
or 65 years and older and were more likely to have been hospitalized or had an emergency visit in the month prior to initiation (Table 1) .
After implementing stabilized IPTWs, measured baseline comorbidities were well-balanced (Figure 2 ).
Under a range of different assumptions, sensitivity analyses suggested a consistent lack of tolerance ranging from 31% to 53% before initiation of ≥90 MME ER/LA opioid therapy (Table 3) .
| Follow-up
Length of follow-up was similar between nontolerant (mean: 275 days) and tolerant patients (mean: 279 days). Nontolerant patients had less subsequent use of opioids with 68% of nontolerant patients filling a prescription more than 90 days after index date, compared with 82%
of patients with prior opioid tolerance (data not shown).
| Clinically recognized opioid poisoning
We identified 2406 opioid poisoning events during the 1-year followup after ≥90 MME ER/LA initiation, of which 3.1% (74) were fatal inhospital deaths. The proportion of clinically recognized poisoning events that were fatal was 3.7% among nontolerant patients and FIGURE 2 Baseline balance among patients initiating 90 morphine milligram equivalents extended-release and long-acting (ER/LA) opioids before and after stabilized inverse probability of tolerance weighting. Abbreviation: IPTW, inverse probability of treatment weights Abbreviations: CI, confidence interval; HR, hazard ratio, MME, morphine milligram equivalents.
2.8% among tolerant patients. The 7-day risk of clinically diagnosed opioid poisoning in patients with prior tolerance was 6.7 (95% CI, 5.7-7.9) while the risk in patients without prior tolerance was 9.2 (95% CI, 7.6-11.1) per 10 000 patients.
In the unadjusted analysis, patients without opioid tolerance were more likely to have a diagnosis of opioid poisoning in the following 7 days (aHR 0-7 = 1.53, 95% CI, 1.21-1.93). After adjustment, the increased risk was attenuated (aHR 0-7 = 1.37, 95% CI, 1.07-1.76) (Table 3) . Sensitivity analyses varying the definition of opioid tolerance all showed an increase in risk of opioid poisoning in the first 7 days among nontolerant patients, with adjusted HRs ranging from 1.27 to 1.65 (Table 3) .
We found that patients without established opioid tolerance prior to initiation were less likely to be diagnosed with opioid poisoning in the 8 to 30 days, 31 to 90 days and 91 to 365 days after initiation ( Figure 3 ). All drug specific estimates were consistently above the null suggesting increased risk of opioid poisoning in the first week; however, these results must be interpreted with caution given the limited sample size for drug specific analyses (Table S2 , Figure S3 ).
In analyses comparing patients receiving ≥90 MME regardless of tolerance to those initiating dosages between 20 and 50 MMEs (N = 396 572), we found that risk of clinically recognized opioid poisoning in the first 7 days was 81% (adjusted hazard ratio 0_7 = 1.81, 95% CI, 1.50-2.20) higher in the ≥90 MME group. The increase in risk was seen throughout the 1-year follow-up period (Table 4) .
| Bias analysis
Using the validation study by Rowe et al, 26 we assumed perfect specificity of the algorithm but then varied the sensitivity by tolerance status ( Figure S4 ). When we assumed 25% sensitivity in tolerant patients and 20% sensitivity in nontolerant patients, the corrected point estimate moved from 1.37 to 1.71. When sensitivity in nontolerant patients was assumed to be 30%, the corrected point estimate was 1.14.
| DISCUSSION
We found that a substantial proportion (38%) of adults with employerbased insurance in the United States initiating ER/LA opioid dosages ≥90 MME were not opioid-tolerant prior to initiation. Fentanyl was the most commonly prescribed high dose ER/LA, and 42% of initiators did not have evidence of prior opioid tolerance. These findings suggest that high dosages of ER/LA opioids may be routinely prescribed against labeled recommendations.
This is the first study we are aware of that analyzes the construct of opioid tolerance in relation to adverse outcomes. Consistent with the prior literature, [11] [12] [13] we found that a large proportion of patients initiating high-dosages of ER/LA opioids did not have label recommended opioid tolerance. The current study builds on published literature, examining the association of tolerance on clinically diagnosed opioid poisoning. [11] [12] [13] We found that nontolerant patients had a 37% increased risk of being diagnosed with opioid poisoning in the first 7 days after initiation. The increased risk was isolated to the first 7 days, after which patients without opioid tolerance at initiation were less likely to be diagnosed with opioid poisoning. This is likely explained by the shorter duration of subsequent opioid exposure in patients without prior Abbreviations: CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weights; MME, morphine milligram equivalents.
tolerance. Because there are no validated algorithms for defining opioid tolerance in claims data, we conducted a range of sensitivity analyses varying the definition of opioid tolerance and consistently found an increased risk in the first week. In addition, our analyses comparing those initiating ER/LA opioids of 90 MME or greater regardless of tolerance, to those initiating lower dosages, replicate prior studies reporting a dose-response relationship with higher opioid dosages being associated with increased risk of overdose. [14] [15] [16] [17] [18] [19] The current findings are limited in that our data only includes clin- This study must be interpreted considering several additional limitations. We had limited information on pain duration and severity, both of which are important in understanding pain management and the context of opioid prescribing decisions. The algorithm to define opioid tolerance in claims data has not been validated, and the 60 MME threshold for opioid tolerance has limited evidentiary support.
Individual patients may require higher (and occasionally lower) baseline opioid levels. 9, 10, 29, 30 The current study describes the proportion of patients with evidence of opioid tolerance and estimates increases in risk of clinically diagnosed opioid poisoning using various tolerance definitions. However, further studies examining clinically relevant dosage cut points and time periods to develop tolerance are needed to support current guidelines and prescribing recommendations.
Opioid equianalgesic conversions, likewise, are a convenient epidemiologic tool for research, but clinically, they have limited utility in opioid conversion and rotation; an individual's tolerance is influenced by many factors not captured in claims data. Accordingly, our current results are not generalizable to all patients initiating opioid therapy.
We included only commercially insured adults, and results may not be generalizable to those with, for example, Medicaid coverage or those who are uninsured. We also assumed that prescriptions were taken as prescribed, based on the days' supply and quantity dispensed.
This may be especially problematic with immediate release opioids which are included in the tolerance definition, as patients are often instructed to take these on an as needed basis. We only observed outpatient prescriptions obtained through the pharmacy benefit, so we missed those paid for in cash, as well as administered in inpatient hospitalizations. However, in both sensitivity analyses dealing with inpatient hospitalizations during baseline, results were stable.
Lastly, as discussed above, we acknowledge that use of ICD-9-CM codes to detect clinically recognized opioid poisoning will result in underreporting of true opioid poisoning. The objective of this study was not to describe incidence rates of opioid poisoning but rather to compare the risk of clinically diagnosed opioid poisoning between tol- 
| CONCLUSIONS
Overall, we found that 38% of patients who were prescribed an ER/LA opioid of a dosage greater than or equal to 90 MME did not have prior 
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